TCG Crossover Management’s Avalo Therapeutics AVTX Stock Holding History

TCG Crossover Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55.8M	Buy	3,017,120 +2,278,737	+309%	+$36M	1.34%	23
2026 Q1	$11M	Buy	738,383 +255,383	+53%	+$3.99M	0.32%	40
2025 Q4	$8.77M	Hold	483,000	–	–	0.29%	37
2025 Q3	$6.14M	Hold	483,000	–	–	0.3%	36
2025 Q2	$2.41M	Hold	483,000	–	–	0.28%	34
2025 Q1	$3.87M	Hold	483,000	–	–	0.53%	33
2024 Q4	$3.59M	Hold	483,000	–	–	0.35%	36
2024 Q3	$4.59M	Buy	+483,000	New	+$4.98M	0.39%	32

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCG Crossover Management's AVTX Position: Q2 2026 in Review

TCG Crossover Management increased its Avalo Therapeutics (AVTX) stake by 309% in Q2 2026, buying an estimated $36M and bringing the position to 3,017,120 shares worth $55.8M. The position accounts for 1.34% of the portfolio, ranked #23.

TCG Crossover Management first reported a position in AVTX in Q3 2024 and has held it in 8 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

TCG Crossover Management held 3,017,120 shares of Avalo Therapeutics worth $55.8M as of Q2 2026.
TCG Crossover Management bought 2,278,737 Avalo Therapeutics shares in Q2 2026, an estimated $36M.
Avalo Therapeutics made up 1.34% of TCG Crossover Management's portfolio in Q2 2026, its #23 holding.
TCG Crossover Management first reported a position in Avalo Therapeutics in Q3 2024 and has held it in 8 quarters since.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.